macular degeneration

Masayo Takahashi (高橋 政代): exciting vision work advancing including with photoreceptors

Dr.-Masayo-Takahashi-高橋-政代.

Masayo Takahashi is a leading stem cell researcher doing translational and clinical research on vision. She’s doing pioneering work on using pluripotent stem cells as a basis for helping patients with vision loss such as due to macular degeneration. She won The Niche’s Stem Cell Person of the Year Award in 2014 and a number …

Masayo Takahashi (高橋 政代): exciting vision work advancing including with photoreceptors Read More »

Stem cell pioneer Masayo Takahashi (高橋 政代) leaves RIKEN

Masayo-Takahashi

In a surprise, Dr. Masayo Takahashi has announced that she has left RIKEN. Takahashi indicates she will be new President of a company called Vision Care, Inc. as part of the Kobe Eye Center. I’ve pasted a picture of Takahashi’s Tweet with translation more toward the bottom of the post. A big thanks to Piero …

Stem cell pioneer Masayo Takahashi (高橋 政代) leaves RIKEN Read More »

Striking improvement in vision in one ACT trial participant

advanced-cell-technology

Advanced Cell Technology (ACT) has confirmed that one of the patient in a clinical trial that it is running for treatment of macular degeneration, the leading cause of blindness worldwide, has shown a striking improvement in vision. The patient reportedly had 20/400 vision prior to treatment and now has 20/40 vision after treatment. ACT uses an …

Striking improvement in vision in one ACT trial participant Read More »

Meet Retina Institute of Japan: translating iPS cells

Retina-Institute-of-Japan

If you are wondering, “How will iPS cells get to help patients?” part of the answer is perhaps the big player and Japanese Institution, Riken and its arm Retina Institute of Japan. The stem cell field is still abuzz about induced pluripotent stem (iPS) cells 7 years after their discovery. This amazing embryonic stem cell-like cells can …

Meet Retina Institute of Japan: translating iPS cells Read More »

As iPS cell studies in humans approach, accessible relevant pre-clinical data remains minimal

When are iPS cell-based therapies ready to be tested in actual people? It’s the million or perhaps even billion dollar question of today in the stem cell field. I realize that perhaps it is also a dangerous question, politically-speaking, for me to ask in a public forum, but patient lives as well as potentially the …

As iPS cell studies in humans approach, accessible relevant pre-clinical data remains minimal Read More »